CADONILIMAB
UNII 6FYG1DS4NW

Substance Identification & Data

This profile provides standardized clinical and technical data for Cadonilimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 6FYG1DS4NW.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2394841-59-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

6FYG1DS4NW

CAS Registry Number

2394841-59-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

CADONILIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C153379

National Cancer Institute reference terminology for clinical and research data.

INN ID

11581

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

JK-159

Identifier assigned by the United States Adopted Names Council.

Substance Type

CADONILIMAB

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Cadonilimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

CADONILIMAB

Common Names & Synonyms

ANTI-PD1/ANTI-CTLA4 BISPECIFIC ANTIBODY AK104

CADONILIMAB [USAN]

Cadonilimab [WHO-DD]

IMMUNOGLOBULIN G1 (235-ALANINE,236-ALANINE,238-ALANINE), ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN-MUS MUSCULUS .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-MUS MUSCULUS HEAVY CHAIN V-D-J REGION) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-MUS MUSCULUS .KAPPA.-CHAIN V-J REGION), DISULFIDE WITH HUMAN-MUS MUSCULUS .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G1-KAPPA ANTI-(HOMO SAPIENS PDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), EACH HEAVY CHAIN BEING FUSED TO A SCFV ANTI- (HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)), MONOCLONAL ANTIBODY, BISPECIFIC, TETRAVALENT; GAMMA1 HEAVY CHAIN ANTI-PDCD1 FUSED TO SCFV ANTI-CTLA4 (1-713) (GAMMA-1 HEAVY CHAIN(1-448) (VH ANTI- PDCD1 (HOMO SAPIENS IGHV3-23*04 (88.7%)-(IGHD)-IGHJ6*01 (90.9%) T123>L (113)) CDR IMGT (8.8.11) (26-33.51-58.97-107) (1-118)-HOMO SAPIENS IGHG1*01, G1M17,1, G1V14 CH2 A1.3, A1.2 (CH1 K120 (215) (119- 216), HINGE 1-15 (217-231), CH2 L1.3>A (235), L1.2>A (236), G1>A (238) (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448))- 20-MER TETRAKIS(TETRAGLYCYL-SERYL) LINKER (449-468)-SCFV HEAVY-LAMBDA ANTICTLA4 (469-713) (VH ANTI-CTLA4 G49>C (512) (HOMO SAPIENS IGHV1- 2*02 (84.7%)-(IGHD)-IGHJ5*01 (90.9%) S128>A (583)) CDR-IMGT (8.8.8) (494-501.519-526.565-572) (469-583)-20-MER TETRAKIS(TETRAGLYCYL-SERYL) LINKER (584-603)-V-LAMBDA ANTI-CTLA4 (HOMO SAPIENS IGLV7-46*01 (85.3%)- IGLJ3*02 (91.7%) G120>C (705)) CDR-IMGT (9.3.9) (629-637.655-657.694- 702) (604-713))); (221-214')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI-PDCD1 (1'- 214') (VKAPPA (MUS MUSCULUS IGKV14-111*01 (86.3%)-IGKJ5*01 (100%)/HOMO SAPIENS IGKV1-16*01 (80.0%)-IGKJ2*01 (81.8%) Q120>A (100), I126>L (106)) CDR-IMGT (6.3.9) (27-32.50-52.89-97) (1'-107')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')); DIMER (227-227'':230-230'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, GLYCOFORM ALFA

PD-1 X CTLA-4 DUAL CHECKPOINT INHIBITOR AK104

cadonilimab [INN]